Edwards CEO Mussallem details U.S. Sapien sales guidance, updates on CoreValve case | Wall Street Beat

January 8, 2013 by MassDevice staff

Edwards Lifesciences CEO Michael Mussallem updates investors on U.S. sales expectations for its flagship Sapien heart valve and says the end might be near for its long legal battle with Medtronic's CoreValve over transcatheter aortic valve implant patents covering Sapien.

MassDevice.com Wall Street Beat

Edwards Lifesciences (NYSE:EW) chairman & CEO Michael Mussallem said the medical device company expects to post U.S. sales of $390 million-$440 million for its flagship Sapien heart valve, adding 200 new sites over the next 2 years to its existing roster of 200 sites.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.